News

This episode focuses on sotagliflozin in type 1 diabetes and other highlights from the ADCES 2024 annual meeting.

Although the study concluded AI had equal or lower rates of critical misses than radiology reports of remarkable chest radiographs, AI had greater critical miss rates.

This new analysis highlights the effect of this selective allosteric tyrosine kinase 2 inhibitor as an oral treatment for moderate-to-severe psoriasis.

A systematic review identified a notable link between the first year of statin discontinuation and the risk of adverse cardiovascular outcomes.

Cascade testing strategies significantly increased the detection of FH, with direct contact yielding a 16-fold higher testing rate, according to the IMPACT-FH study.

Findings suggest the benefit of early HCV detection and treatment with DAAs for improving liver-related outcomes and reducing fibrotic burden.

Rates of adverse events leading to discontinuation were similar between populations of moderate-to-severe psoriasis and psoriatic arthritis.

Laurence Sperling, MD, offers perspective on multiple topics within the evolving field of lipid management and dyslipidemia.

These data on the efficacy of bimekizumab suggest positive therapeutic effects on nail, scalp, and genital lesions as well as quality of life.

Estimates based on NHANES data suggest 15.6 million US adults have used a potentially hepatotoxic botanical herbal and dietary supplement product within the past 30 days.

Higher olpasiran doses sustained a ~50% placebo-adjusted mean reduction in Lp(a) levels nearly 1 year after the final dose.

A new recommendation statement cites a lack of current evidence to assess the benefits of iron deficiency screening and supplementation in pregnant individuals.

A phase 2 trial shows tofacitinib improves autoimmune conditions in Down syndrome, with notable skin health benefits and a good safety profile.

Results suggest paternal hepatitis B virus infection prior to pregnancy is associated with a 40% increased risk of congenital heart diseases in their children.

Yosipovitch spoke in this interview about the clinical trials leading up to the FDA approval of his nemolizumab for patients with prurigo nodularis.

Participants with greater poor sleep and renal function biomarker scores had a 5.45-fold greater risk of developing severe MASLD.

Alkhouri describes how Agile 3 + and Agile 4 scoring may help address issues with low positive predictive value seen with other noninvasive tests for MASLD fibrosis and cirrhosis.

In this episode, hosts react to the announced CMS list prices for the first 10 drugs chosen for negotiation as part of the Inflation Reduction Act.

On August 19, 2024, Liquidia Corporation announced the FDA's tentative approval of treprostinil inhalation powder for adults with PAH and PH-ILD.

Identified proteins impacted by the presence of atopic dermatitis may provide clinicians a better understanding of how to treat it.

A new analysis suggests HbA1c may be more informative to fatty liver disease severity than BMI, and should be included in screenings.

A randomized clinical trial found significant improvements in key blood parameters for anemia after grape syrup intervention compared with placebo.

In this interview, Yosipovitch discusses his team’s findings on nemolizumab and the significance of the drug’s FDA approval for those with prurigo nodularis.

A recent study found that noise exposure of power looms (≥ 85 decibels) puts workers at risk of their overall blood pressure increasing.

Moderate alcohol consumption did not significantly impact liver-related parameters in patients with the Pi*MZ and Pi*ZZ genotypes of alpha-1 antitrypsin deficiency.

This analysis suggests additional support may be required for tildrakizumab-associated adverse drug reactions, given these new insights.

The first of 2 episodes on ADCES 2024, this episode focuses on sessions and presentations hosts Isaacs and Bellini participated in during the meeting.